Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic/Myeloproliferative Diseases: early-phase trial registry
A small indexed set (8 trials) with no open enrollment listed right now.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count
Myelodysplastic/Myeloproliferative Diseases: 8 US clinical trials tracked, none currently recruiting.
Myelodysplastic/Myeloproliferative Diseases is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition myelodysplasticmyeloproliferative-diseases
OPEN 0 | RECR 0% | LATE 0 | EARLY 8 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Myelodysplastic/Myeloproliferative Diseases has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic/Myeloproliferative Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic/Myeloproliferative Diseases is recruiting below its size-band peers.
0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myelodysplastic/Myeloproliferative Diseases research.
Fred Hutchinson Cancer Center accounts for 2 of 8 trials (25%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Myelodysplastic/Myeloproliferative Diseases trials plan to enrol fewer than 100 people.
Median target enrolment is 34 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Myelodysplastic/Myeloproliferative Diseases research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
NCT00003816
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00410657
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Case Comprehensive Cancer Center
NCT00054327
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center
NCT00109993
Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders
Fred Hutchinson Cancer Center
NCT00002792
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Northwestern University
NCT00004896
Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
University of Wisconsin, Madison
NCT00052832
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00006042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic/Myeloproliferative Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic/Myeloproliferative Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic/Myeloproliferative Diseases page
8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Myelodysplastic/Myeloproliferative Diseases trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Fred Hutchinson Cancer Center sponsors the most Myelodysplastic/Myeloproliferative Diseases trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic/Myeloproliferative Diseases condition card totals 8 registered trials; most-linked intervention cyclophosphamide; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.